Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash from Financing Activities (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Cash from Financing Activities for 6 consecutive years, with $2000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Cash from Financing Activities fell 99.6% year-over-year to $2000.0, compared with a TTM value of $839000.0 through Sep 2025, down 41.53%, and an annual FY2024 reading of $2.2 million, up 15.54% over the prior year.
  • Cash from Financing Activities was $2000.0 for Q1 2025 at Barinthus Biotherapeutics, down from $837000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $121.8 million in Q1 2021 and bottomed at -$1.4 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $15.1 million, with a median of $358000.0 recorded in 2024.
  • Peak annual rise in Cash from Financing Activities hit 5277.78% in 2022, while the deepest fall reached 100.13% in 2022.
  • Year by year, Cash from Financing Activities stood at $9000.0 in 2021, then surged by 5277.78% to $484000.0 in 2022, then tumbled by 77.48% to $109000.0 in 2023, then skyrocketed by 667.89% to $837000.0 in 2024, then crashed by 99.76% to $2000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for BRNS at $2000.0 in Q1 2025, $837000.0 in Q4 2024, and $465000.0 in Q3 2024.